Clinical Trials
9
Active:2
Completed:2
Trial Phases
3 Phases
Phase 1:7
Phase 3:1
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
Phase 1
7 (77.8%)Not Applicable
1 (11.1%)Phase 3
1 (11.1%)ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy
Not Applicable
Not yet recruiting
- Conditions
- Locally Advanced or Metastatic NSCLC
- Interventions
- Drug: ASKC202+ Limertinib
- First Posted Date
- 2025-08-07
- Last Posted Date
- 2025-08-07
- Lead Sponsor
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.
- Target Recruit Count
- 286
- Registration Number
- NCT07109531
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, China
A Phase 1 Clinical Trial Examining the Safety and Pharmacokinetics on Osteoarthritic Knee Pain of ASKC200
Phase 1
Not yet recruiting
- Conditions
- Osteoarthritis, KneePain
- Interventions
- Drug: 5% ASKC200Drug: 1% ASKC200
- First Posted Date
- 2024-09-26
- Last Posted Date
- 2024-09-26
- Lead Sponsor
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT06614608
- Locations
- 🇨🇳
Beijing Hospital, Beijing, Beijing, China
Drug-drug Interaction Study Beteewn ASK120067 and Rifampicin or Itraconazole
Phase 1
Completed
- Conditions
- Locally Advanced or Metastatic NSCLC
- Interventions
- Drug: Rifampicin; ASK120067Drug: ASK120067;itraconazole
- First Posted Date
- 2022-11-30
- Last Posted Date
- 2022-11-30
- Lead Sponsor
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT05631678
- Locations
- 🇨🇳
Drum Tower Hospital of Nanjing University School of Medical, Nanjing, Jiangsu, China
Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2023-03-06
- Lead Sponsor
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.
- Target Recruit Count
- 150
- Registration Number
- NCT05306132
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳Xiangya Hospital Central South University, Changsha, Hunan, China
🇨🇳Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
Phase 1
Active, not recruiting
- Conditions
- Malignant Solid Tumor
- Interventions
- Drug: ASKB589 Injection
- First Posted Date
- 2020-11-17
- Last Posted Date
- 2025-09-11
- Lead Sponsor
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.
- Target Recruit Count
- 199
- Registration Number
- NCT04632108
- Locations
- 🇨🇳
Beijing cancer hospital, Beijing, Beijing Municipality, China
🇨🇳Linyi cancer hospital, Linyi, Shandong, China
- Prev
- 1
- 2
- Next
News
No news found